Anti-Mouse CD70 [FR70] In Vivo Antibody - Low Endotoxin

(No reviews yet) Write a Review
SKU:
IVMB0320
Product Type:
In Vivo Monoclonal Antibody
Clone:
FR70
Protein:
CD70
Isotype:
IgG2b k
Reactivity:
Mouse
Synonyms:
TNFSF7
Synonyms:
KI-24 antigen
Synonyms:
CD27 Ligand
Synonyms:
CD27L
Research Area:
Costimulatory Molecules
Research Area:
Immunology
Endotoxin Level:
Low Endotoxin
Host Species:
Rat
Applications:
FA
Applications:
FC
Applications:
In Vivo
Applications:
WB

Description

Product Name:Anti-Mouse CD70 (Clone FR70) In Vivo Antibody - Low Endotoxin
Product Code:IVMB0320
Size:1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:FR70
Protein:CD70
Product Type:Monoclonal Antibody
Synonyms:TNFSF7, KI-24 antigen, CD27 Ligand, CD27L
Isotype:IgG2b k
Reactivity:Mouse
Applications:FA, FC, In Vivo, WB
Formulation:This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:≥95% monomer by analytical SEC ⋅ >95% by SDS Page
Product Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:FA, FC, In Vivo, WB
Reactivity:Mouse
Host Species:Rat
Specificity:FR70 activity is directed against mouse CD70.
Antigen Distribution:Mouse CD70 is transiently expressed on the surfaces of antigen-activated B and T cells, natural killer cells, and mature dendritic cells. CD70 is also aberrantly expressed on malignant cancer cells.
Immunogen:BALB/c mouse B lymphoma A20.J2
Concentration:≥ 5.0 mg/ml
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Formulation:This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:≥95% monomer by analytical SEC ⋅ >95% by SDS Page
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

CD70, a type II transmembrane glycoprotein of the TNF family with cytokine activity, is the ligand for the CD27 receptor1. Mouse CD70 (mCD70) has a potent co-stimulatory effect on T cell proliferation1 and acts as an immune-checkpoint2. In mouse, but not in humans, the CD70-CD27 axis mediates a negative feedback system that enables the immune system to modulate hematopoiesis2. Additionally, CD70-CD27 interactions are important to the formation of memory and plasma B cells. Immunotherapies that aim to eradicate tumor cells by targeting CD70 overexpression are being developed2. FR70 inhibits mCD70 binding to mCD27-Ig, a recombinant soluble form of mCD271, as well as to mCD27 in vitro3,4 and in vivo5. FR70 was produced by immunizing an F344/DuCrj rat with A20 cells and fusing the splenocytes with P3U1 cells to create hybridoma lines1. HAT selection was performed, and FR70 was identified by its strong reactivity against mCD70-BHK21 cells. Blocking with FR70 can prolong graft acceptance6,7. When mouse cardiac allogenic graft recipients are treated with FR70, tolerogenic dendritic cells and T regulatory cells are induced, resulting in decreased cytotoxic T lymphocyte proliferation as well as long-term graft acceptance6. Blocking with FR70 also prolongs mouse corneal graft survival7.

Protein:CD70
Function:T-B cell cross-stimulation
Ligand/Receptor:CD27
Research Area:Costimulatory Molecules, Immunology
Shipping:2-8°C
PubMed:CD70
NCBI Gene Bank ID:21948
UniProt:CD70
View AllClose

0 Reviews

View AllClose

Related Products